The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Battle with Insurance Companies to Obtain Prescriptions

The Battle with Insurance Companies to Obtain Prescriptions

March 17, 2018 • By Philip Seo

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In a time during which Congress seems increasingly paralyzed by complexity, it will likely be the states that will lead the way. With the recent revelations regarding Aetna’s preapproval review/nonreview practices, patients across the country are likely starting to wonder how carefully their records were scrutinized before their request for a biologic (or another inconveniently expensive intervention) was rejected. Colorado, Washington and Connecticut have already initiated their own reviews of Aetna’s practices, and other states are bound to follow suit.8

You Might Also Like
  • Opinion: Insurance Companies Use Medically and Fiscally Irresponsible Formularies
  • PRACTICE PAGE: The ACR Takes on Insurance Companies
  • Two Years of Helping Patients Obtain Prescriptions
Explore This Issue
March 2018
Also By This Author
  • The Story of the N95 Mask

Over the next several months, we are likely to get a crash course in how insurance companies actually make the decisions that impact so many of our patient’s lives.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Biosimilars were supposed to have rendered most of these issues moot. Alternatives to brand-name biologics creates competition, and competition lowers prices. Lower prices remove the profit motive for the preapproval process, and insurance companies would move on to bigger game. Quod erat demonstrandum.

So what happened? For all their promises, biosimilars have had trouble establishing a foothold in the U.S. Of the 240 biosimilars in development, only nine have been approved by the U.S. Food and Drug Administration, and only three are now in use.9 It gets worse: I defy you to find a colleague who has deliberately switched a patient to a biosimilar.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Part of the problem is the birthing process associated with new statutes. Legislators may write the laws, but it is up to the courts to determine what the laws mean. There are now multiple lawsuits winding their way through the American court system, each designed to prevent biosimilars from seeing the light of day. These delays cost money. Add to this uncertainties regarding intellectual property, and the costs continue to mount. Thus, in the U.S., use of a biosimilar may save an insurance company only 15% of the costs associated with using the brand-name originator, a cost savings that is easily offset by the sweetheart discounts engineered by insurance companies for steering patients toward biologic X, rather than biologic Y.10 Ironically, patient assistance programs contribute to the problem by making it cheaper for many patients to continue to take brand-name biologics, rather than transition to a biosimilar.

Of the 240 biosimilars in development, only nine have been approved by the U.S. Food & Drug Administration, & only three are now in use. It gets worse: I defy you to find a colleague who has deliberately switched a patient to a biosimilar.

Eventually, statute will be turned into precedent, and once a clear pathway from development to market has been carved by the courts, the cost savings should start to emerge. In Sweden, for example, the availability of anti-TNF biosimilars has caused the price of drugs in this class to drop by 39%; prices in the U.S. will eventually follow suit.11 The Rand Corporation estimates that the use of biosimilars will lead to $54 billion in healthcare cost savings from 2017 to 2026.12 We can only hope.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Legal, Legislation & Advocacy, Opinion, Pharma Co. News, Rheuminations Tagged With: drug benefits, pharmacy benefit managers, prescriptionIssue: March 2018

You Might Also Like:
  • Opinion: Insurance Companies Use Medically and Fiscally Irresponsible Formularies
  • PRACTICE PAGE: The ACR Takes on Insurance Companies
  • Two Years of Helping Patients Obtain Prescriptions
  • Are Insurance Companies’ Medication Directives Fiscally, Medically Questionable?

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)